Cancer Institute A national cancer institute
designated cancer center

Alan M. Garber

Publication Details

  • Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

    Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP. Ann Intern Med. 2011; 154 (1): 1-11

    Warfarin reduces the risk for ischemic stroke in patients with atrial fibrillation (AF) but increases the risk for hemorrhage. Dabigatran is a fixed-dose, oral direct thrombin inhibitor with similar or reduced rates of ischemic stroke and intracranial hemorrhage in patients with AF compared with those of warfarin.

    PubMedID: 21041570

Stanford Medicine Resources:

Footer Links: